Abstract Background Immunotherapy has revolutionized the treatment of ovarian cancer (OC). but different immune microenvironments often constrain the efficacy of immunotherapeutic interventions. Therefore. there is an imperative to delineate novel immune subtypes for development of efficacious immunotherapeutic strategies. https://fitnessgravesyardes.shop/product-category/lower-pca-board/